Zai Lab Limited today announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults. "There ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback